plant
abl
perform
posttransl
matur
therapeut
protein
requir
function
biolog
activ
suitabl
vivo
pharmacokinet
plant
lowcost
largescal
product
platform
recombin
biopharmaceut
protein
vaccin
antibodi
plant
howev
lack
mechan
process
authent
human
nglycosyl
impos
major
limit
use
express
system
therapeut
glycoproduct
effort
made
circumv
plantspecif
nglycosyl
well
supplement
plant
endogen
system
human
glycosyltransferas
nonimmunogen
human
nglycan
product
herein
review
studi
potenti
plant
serv
product
system
therapeut
prophylact
biopharmaceut
especi
focus
recombin
vaccin
antibodi
new
express
strategi
overcom
exist
problem
associ
product
plant
v
accin
antibodi
common
therapeut
modal
prophylaxi
treatment
sever
infecti
diseas
cancer
biopharmaceut
protein
requir
industrialscal
product
due
strong
market
demand
tradit
microbi
ferment
mammalian
cell
use
produc
recombin
protein
human
pathogen
contamin
high
product
cost
hamper
animalbas
express
system
compel
altern
product
platform
develop
instanc
accord
world
health
organ
survey
human
mortal
endem
canin
rabi
estim
death
per
year
last
sever
decad
antirabi
equin
immunoglobulin
defunct
precipit
worldwid
shortag
antirabi
immunoglobulin
particularli
impact
develop
countri
sinc
concern
safeti
animalderiv
product
sourc
anim
pathogen
rais
gener
control
lethal
rabi
viru
human
anim
requir
postexposur
prophylaxi
pep
combin
administr
vaccin
immunoglobulin
rig
thu
shortag
vaccin
immunoglobulin
develop
countri
put
rabi
patient
danger
addit
shortag
parenter
vaccin
administr
via
needl
inject
increas
treatment
cost
anoth
difficulti
econom
challeng
develop
countri
dr
hilari
koprowski
cowork
recogn
needl
inject
method
hurdl
global
vaccin
applic
accordingli
develop
oral
spray
polio
vaccin
subsequ
conduct
oral
vaccin
trial
belgian
congo
sinc
oral
spray
method
becom
standard
administr
model
polio
vaccin
eventu
contribut
erad
polio
worldwid
vaccin
gener
produc
anim
organ
cell
inher
risk
anim
pathogen
contamin
recent
advanc
field
molecular
immunolog
biotechnolog
creat
opportun
use
recombin
vaccin
monoclon
antibodi
mab
prevent
control
infecti
diseas
cancer
plant
genet
engin
appli
express
valuabl
recombin
biopharmaceut
protein
industri
scale
advantag
plant
express
system
includ
largescal
product
capac
lack
anim
pathogen
contamin
low
cost
biomass
product
compar
mammalian
system
plant
addit
suitabl
extens
posttransl
modif
protein
requir
full
biolog
activ
includ
nglycosyl
manner
similar
mammalian
express
system
koprowski
anticip
global
use
vaccin
would
requir
low
cost
eas
mainten
effici
distribut
thu
initi
develop
plant
express
system
viabl
altern
platform
product
oral
vaccin
therapeut
antibodi
infecti
diseas
cancer
sinc
success
divers
plantderiv
vaccin
infecti
diseas
rabi
hiv
sever
acut
respiratori
syndrom
sar
smallpox
hepat
b
report
monoclon
antibodi
neutral
virus
control
cancer
cell
growth
success
produc
plant
includ
highli
valuabl
glycoprotein
immunotherapeut
action
antibodydepend
cellular
cytotox
adcc
complementdepend
cytotox
cdc
other
herein
primarili
discuss
requir
effici
product
therapeut
recombin
vaccin
antibodi
plant
molecular
biofarm
harmon
regulatori
factor
transcript
translat
posttransl
event
gene
express
hiatt
colleagu
report
express
fold
assembl
bioactiv
fulllength
heavyand
lightchain
monoclon
antibodi
tobacco
plant
gener
heavyand
lightchain
gene
either
express
separ
individu
plant
express
singl
plant
gener
obtain
crosspollin
two
transgen
plant
anoth
strategi
express
heavyand
lightchain
gene
singl
plant
cotransform
two
gene
express
vector
singletransform
singl
express
vector
carri
two
gene
express
cassett
depend
specif
requir
differ
strategi
employ
higher
express
level
establish
transgen
line
within
short
period
time
regardless
strategi
employ
care
select
express
regulatori
element
includ
promot
termin
essenti
avoid
unbalanc
express
lightand
heavychain
gene
gene
silenc
complet
antibodi
igg
iga
even
igm
success
express
plant
furthermor
multipl
monoclon
antibodi
express
singl
plant
via
crossfertil
individu
transgen
plant
express
differ
targetbind
monoclon
antibodi
chimer
fab
singlechain
variabl
fragment
scfv
gene
success
express
plant
nativ
fullsiz
antibodi
anim
origin
recombin
antibodiesfrag
express
plant
differ
biolog
activ
size
glycan
structur
thu
sizebas
select
recombin
antibodi
posttransl
modif
regul
subcellular
target
includ
glycan
structur
key
issu
plantbas
antibodi
express
divers
form
antibodi
fullsiz
larg
singlechain
camelid
heavychain
fab
fragment
scfv
biospecif
antibodi
express
therapeut
diagnost
purpos
variou
plantbas
express
system
plant
recombin
therapeut
glycoprotein
properli
fold
assembl
typic
includ
nglycosyl
process
core
glycostructur
similar
mammal
thu
plant
capabl
produc
human
glycoprotein
recombin
therapeut
antibodi
treatment
infecti
diseas
cancer
produc
transgen
plant
system
tabl
glycosyl
antibodi
carri
differ
manner
plant
cell
mammalian
cell
glycosyl
modifi
biolog
activ
antibodi
regul
stabil
cdc
adcc
well
immunogen
allergen
anim
human
nevertheless
antibodi
express
plant
similar
antigen
bind
counterpart
express
mammalian
system
glycoengin
effect
tool
knockout
plantspecif
glycan
transferas
gene
knockin
mammalian
transferas
gene
add
sialic
acid
fucos
galactos
nglycan
plant
product
system
engin
similar
mammalian
express
system
term
glycosyl
thu
avoid
concern
plantspecif
glycan
plant
addit
limit
factor
low
level
recombin
protein
express
yield
recombin
antibodi
plant
may
improv
sever
approach
choic
plant
speci
transform
transform
method
codon
optim
design
recombin
gene
express
cassett
subcellular
local
recombin
antibodi
choic
specif
plant
tissu
harvest
time
biomass
harvest
local
accumul
protein
subcellular
compart
er
chloroplast
mitochondria
vacuol
import
ensur
correct
fold
assembl
consequ
protein
stabil
biofunction
plant
specif
tissu
includ
leaf
seed
root
harvest
purifi
recombin
therapeut
protein
gener
antibodi
fc
region
carri
glycosyl
site
target
er
glycosyl
ensur
avoid
plantspecif
glycan
residu
well
proper
fold
assembl
enhanc
accumul
recombin
antibodi
within
er
tobacco
alfalfa
legum
includ
foliag
veget
chosen
express
exogen
protein
fresh
plant
leaf
tissu
wherea
corn
rapese
use
accumul
protein
dri
tissu
seed
use
high
protein
seed
tissuespecif
promot
betaphaseolin
promot
common
bean
oleosin
promot
brassica
speci
plant
recombin
protein
local
plant
subcellular
compart
nucleu
plastid
mitochondria
use
specif
signal
peptid
sequenc
recombin
gene
express
cassett
transcript
posttransl
modif
plant
control
express
harvest
level
recombin
therapeut
protein
plant
biomass
essenti
featur
suitabl
altern
express
system
compar
anim
cellbas
product
system
koprowski
colleagu
achiev
mark
progress
express
recombin
vaccin
plant
tabl
success
plantderiv
recombin
vaccin
achiev
harmon
plant
genet
engin
molecular
immunolog
two
administr
strategi
intraven
usag
recombin
vaccin
protein
purifi
plant
biomass
oral
administr
edibl
part
plant
express
recombin
vaccin
protein
without
downstream
purif
process
concern
regard
retent
immunocompet
recombin
vaccin
protein
purifi
plant
tissu
reflect
level
specif
antibodi
product
anim
plantderiv
oral
vaccin
induc
mucos
humor
immun
respons
intestin
plantderiv
oral
vaccin
distinct
advantag
tradit
vaccin
includ
lower
cost
due
conveni
storag
easi
usag
without
needl
koprowski
colleagu
report
success
plantderiv
recombin
vaccin
bacteri
viral
diseas
cancer
tabl
vivo
immun
respons
anim
model
cholera
toxin
b
subunit
ctb
fuse
three
copi
tandemli
repeat
diabetesassoci
autoantigen
b
chain
human
insulin
express
lownicotin
tobacco
retain
receptor
bind
specif
potenti
effect
strategi
prevent
treat
autoimmun
diabet
induc
oral
toler
parenter
immun
plantderiv
recombin
viruslik
particl
carri
chimer
hybrid
tobacco
mosaic
viru
tmv
coat
protein
amino
acid
sequenc
murin
zona
pellucida
protein
induc
immun
respons
epitop
mice
order
optim
plant
bioreactor
recombin
vaccin
product
sever
concern
need
address
includ
loss
immunogen
degrad
gastrointestin
microenviron
risk
unwant
plant
biochem
contamin
nicotin
alkaloid
low
express
level
recombin
vaccin
protein
instanc
alkaloid
remov
purif
process
prior
usag
glycomodif
avoid
potenti
immunogen
nglycan
plantderiv
pharmaceut
plant
mammalian
nglycan
share
common
core
structur
man
glcnac
plant
mammal
secret
protein
nglycosyl
depend
addit
sugar
attach
core
structur
plant
nglycan
classifi
three
group
oligomannosid
paucimannosid
complex
type
nglycan
oligomannos
type
nglycan
five
nine
mannos
residu
attach
nacetylglucosamin
glcnac
endoplasm
reticulum
er
highli
conserv
plant
human
glycosyl
process
golgi
complex
differ
plant
human
plant
fucos
fuc
residu
attach
proxim
glcnac
andor
b
xylos
xyl
link
bmannos
man
residu
core
structur
yield
plant
specif
matur
nglycan
golgi
complex
contrast
human
nglycan
harbor
fuc
core
glycan
structur
without
xyl
residu
termin
sialic
acid
attach
b
galactos
gal
residu
glcnac
plantspecif
paucimannosid
type
nglycan
consid
typic
vacuolar
nglycan
modifi
oligosaccharid
contain
fuc
link
glcnac
andor
b
xyl
attach
bman
residu
man
glcnac
man
glcnac
matur
plant
nglycan
structur
within
golgi
complex
differ
human
nglycosyl
hamper
product
commerci
recombin
therapeut
glyoprotein
human
origin
plant
advanc
glycoengin
plant
biopharmaceut
protein
lead
increas
biopharmaceut
market
approxim
billion
annual
unit
state
worldwid
pharmaceut
market
estim
grow
trillion
year
koprowski
colleagu
emphas
practic
develop
like
futur
trend
plant
molecular
biopharmaceut
industri
plant
unlik
human
matur
nglycan
structur
carri
plantspecif
immunogen
b
xyl
fuc
residu
lack
termin
b
gal
sialic
acid
residu
thu
glycomodif
includ
remov
nonmammalian
glycan
residu
concomit
addit
termin
sialic
acid
residu
thu
increas
immunogen
potenti
longev
protein
human
respect
knockout
rnai
approach
use
modul
nglycosyl
process
remov
plantspecif
glycan
epitom
addit
knockin
strategi
appli
express
human
b
galactosyltransferas
elong
b
galactos
plant
essenti
carri
sialic
acid
residu
termin
glycan
residu
mammalian
glycoprotein
sialic
acid
link
termin
b
b
gal
residu
termin
sialic
acid
affect
biolog
activ
longev
therapeut
glycoprotein
howev
plant
cell
carri
heterolog
enzym
gene
sialyl
glycoprotein
thu
plant
nglycomodif
obtain
sialic
acid
residuetermin
glycan
via
express
exogen
enzym
requir
catalyz
sialic
acid
synthesi
transport
golgi
apparatu
transfer
sialic
acid
b
galactosyl
glycan
divers
strategi
exist
reduc
potenti
allergen
immunogen
plant
specif
nglycan
recombin
therapeut
protein
one
approach
elimin
nglycosyl
site
point
mutat
amino
acid
thu
prevent
glycosyl
recombin
protein
howev
strategi
work
therapeut
glycoprotein
requir
nglycosyl
vivo
stabil
biolog
activ
gomord
colleagu
report
addit
remov
nglycan
residu
sever
therapeut
recombin
protein
improv
halflif
biolog
activ
second
approach
retain
recombin
protein
er
transfer
golgi
complex
plantspecif
glycan
structur
matur
recombin
protein
retain
er
contain
oligomannosetyp
nglycan
commonli
found
plant
mammal
thu
probabl
immunogen
human
anim
protein
local
er
eukaryot
cell
achiev
via
addit
retent
motif
kdel
hdel
ctermin
end
secretori
protein
tobacco
plant
antibodi
contain
kdel
sequenc
fuse
ctermin
end
heavi
chain
oligomannos
nglycan
six
nine
mannos
residu
antibodi
fuse
kdel
retent
signal
heavi
light
chain
oligomannos
nglycan
koprowski
colleagu
report
plantderiv
antibodi
oligomannos
nglycan
less
stabl
compar
human
counterpart
mice
indic
oligomannos
nglycan
structur
affect
biolog
properti
vivo
halflif
antibodi
oligomannosid
group
mice
likewis
reduc
rel
mammalianderiv
antibodi
probabl
due
endocytosi
degrad
follow
bind
mannos
receptor
previous
observ
oligomannos
glycosyl
antibodi
express
cho
cell
rapid
disappear
antibodi
reduc
activ
passiv
immun
human
interfer
vaccin
antibodi
applic
rabi
prophylaxi
third
approach
inhibit
golgi
glycoslytransferas
express
use
knockout
mutant
prevent
synthesi
matur
plantspecif
complex
nglycan
arabidopsi
thaliana
cgl
mutant
defici
glycosyltransferas
accumul
mainli
oligomannos
structur
man
glcnac
carri
termin
glcnac
residu
link
man
without
allergen
immunogen
plant
specif
fuc
b
xyl
gener
glycosyltransferas
defici
lethal
mice
howev
knockout
plant
mutant
show
advers
impact
plant
develop
morpholog
glycan
structur
advantag
easili
ad
gal
sialic
acid
residu
termin
glcnac
human
nglycosyl
plant
inde
express
gene
encod
transferas
galactos
sialic
acid
residu
attempt
arabidopsi
thaliana
produc
antihiv
viru
antibodi
nglycosyl
analysi
reveal
termin
sialic
acid
attach
gal
absenc
fuc
b
xyl
residu
plantderiv
antibodi
evid
plant
suitabl
altern
express
system
therapeut
glycoprotein
humanlik
glycosyl
pattern
koprowski
colleagu
biotechnolog
foundat
laboratori
thoma
jefferson
univers
wistar
institut
major
group
introduc
plant
altern
platform
product
function
therapeut
protein
mainli
due
rapid
progress
plant
biotechnolog
genet
engin
enabl
humanlik
glycosyl
pattern
therapeut
glycoprotein
advantag
plantbas
product
system
animalbas
one
therapeut
prophylact
biopharmaceut
includ
lower
product
cost
reduc
product
time
effort
obtain
plant
biomass
lack
mammalian
pathogen
contamin
eas
scalabl
